This article originally appeared on ProPublica. ProPublica is a Pulitzer Prize-winning investigative newsroom. Sign up for The Big Story newsletter to receive stories like this one in your inbox.

Three years after one of the largest medical device recalls in history, the fallout – health-wise and financial – continues to impact many patients with sleep apnea. Now a critical deadline is ...

In 2021, a widely used breathing device manufactured by Philips was the subject of a safety recall. Now, new reporting shows that the replacement machines sent out to customers might also pose ...

Medical device company Philips reached a settlement Monday to shell out $1.1 billion to cover hundreds of personal injury lawsuits linked to its respiration and sleep apnea machines. The manufacturer ...

Add Yahoo as a preferred source to see more of our stories on Google. The Philips Center is seen on Jan. 27, 2015, in Amsterdam, Netherlands. Philips, the company behind a global recall of sleep apnea ...

Medical device maker Phillips formally entered into a consent decree that stops the company from selling sleep apnea machines in the United States over health concerns that include cancer. The decree ...

Add Yahoo as a preferred source to see more of our stories on Google. Philips said Monday it will stop selling its sleep apnea machines in the US, more than two years after the Dutch manufacturer ...

Earlier this week, the U.S. Department of Justice, representing the Food and Drug Administration and healthcare technology company Philips came to an agreement to no longer sell their sleep therapy or ...

Adding additional wounds to Philips bruising few years dealing with its major recall of CPAP and BiPAP machines, a new issue has arisen in a swath of its CPAP machines not included in the 2021 notice.

WASHINGTON — A device made by Philips Respironics for treating sleep apnea should be monitored closely when in use because it can overheat, according to federal regulators. The Food and Drug ...

The move comes as Philips has agreed to a consent decree with the Food and Drug Administration and the Department of Justice that could cost the company nearly $400 million. In June 2021, Philips ...